Analysts Expect Entellus Medical, Inc. (ENTL) to Post -$0.38 Earnings Per Share
Analysts predict that Entellus Medical, Inc. (NASDAQ:ENTL) will report ($0.38) earnings per share (EPS) for the current quarter, according to Zacks. Two analysts have made estimates for Entellus Medical’s earnings. The lowest EPS estimate is ($0.45) and the highest is ($0.33). Entellus Medical reported earnings of ($0.39) per share in the same quarter last year, which suggests a positive year over year growth rate of 2.6%. The firm is expected to issue its next quarterly earnings report on Tuesday, February 20th.
According to Zacks, analysts expect that Entellus Medical will report full-year earnings of ($1.55) per share for the current year, with EPS estimates ranging from ($1.77) to ($1.33). For the next fiscal year, analysts expect that the firm will report earnings of ($1.02) per share, with EPS estimates ranging from ($1.21) to ($0.78). Zacks Investment Research’s earnings per share calculations are an average based on a survey of sell-side research analysts that that provide coverage for Entellus Medical.
Several analysts recently commented on the company. Zacks Investment Research cut Entellus Medical from a “hold” rating to a “sell” rating in a report on Tuesday, July 11th. BidaskClub upgraded Entellus Medical from a “buy” rating to a “strong-buy” rating in a report on Friday, July 14th. Piper Jaffray Companies restated a “buy” rating on shares of Entellus Medical in a report on Wednesday, July 12th. Finally, Canaccord Genuity restated a “hold” rating and set a $17.00 price target on shares of Entellus Medical in a report on Tuesday, October 17th. Two research analysts have rated the stock with a sell rating, three have assigned a hold rating and four have given a buy rating to the company. Entellus Medical has an average rating of “Hold” and a consensus price target of $21.17.
Shares of Entellus Medical (NASDAQ:ENTL) traded down $0.51 during mid-day trading on Wednesday, reaching $15.64. The company had a trading volume of 176,973 shares, compared to its average volume of 139,355. Entellus Medical has a 1-year low of $11.47 and a 1-year high of $20.34. The company has a current ratio of 3.87, a quick ratio of 3.53 and a debt-to-equity ratio of 0.19.
In related news, VP Stephen R. Paidosh sold 25,000 shares of the stock in a transaction on Wednesday, September 13th. The stock was sold at an average price of $17.54, for a total value of $438,500.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, VP Timothy B. Petrick sold 2,000 shares of the stock in a transaction on Friday, September 22nd. The shares were sold at an average price of $18.00, for a total value of $36,000.00. The disclosure for this sale can be found here. Over the last quarter, insiders sold 92,150 shares of company stock worth $1,740,652. 7.70% of the stock is owned by company insiders.
Several institutional investors have recently made changes to their positions in the company. Kopp Investment Advisors LLC increased its position in shares of Entellus Medical by 0.5% during the 2nd quarter. Kopp Investment Advisors LLC now owns 11,874 shares of the medical technology company’s stock valued at $197,000 after purchasing an additional 55 shares during the last quarter. Parametric Portfolio Associates LLC increased its position in shares of Entellus Medical by 5.6% during the 1st quarter. Parametric Portfolio Associates LLC now owns 10,888 shares of the medical technology company’s stock valued at $150,000 after purchasing an additional 573 shares during the last quarter. First Mercantile Trust Co. increased its position in shares of Entellus Medical by 45.3% during the 2nd quarter. First Mercantile Trust Co. now owns 8,206 shares of the medical technology company’s stock valued at $136,000 after purchasing an additional 2,557 shares during the last quarter. Bank of America Corp DE increased its position in shares of Entellus Medical by 53.8% during the 1st quarter. Bank of America Corp DE now owns 7,418 shares of the medical technology company’s stock valued at $102,000 after purchasing an additional 2,594 shares during the last quarter. Finally, Nationwide Fund Advisors increased its position in shares of Entellus Medical by 61.7% during the 2nd quarter. Nationwide Fund Advisors now owns 6,903 shares of the medical technology company’s stock valued at $114,000 after purchasing an additional 2,635 shares during the last quarter. 70.25% of the stock is owned by hedge funds and other institutional investors.
Entellus Medical Company Profile
Entellus Medical, Inc is a medical technology company. The Company is focused on delivering patient and physician experiences through products designed for the minimally invasive treatment of chronic and recurrent sinusitis in both adult and pediatric patients. Its three core product lines, XprESS Multi-Sinus Dilation Systems, MiniFESS Surgical Instruments, and FocESS Imaging & Navigation, are designed to enable ear, nose and throat (ENT), physicians to perform a range of procedures in the ENT physician office and to simplify operating room-based treatment.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Entellus Medical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Entellus Medical Inc. and related companies with MarketBeat.com's FREE daily email newsletter.